The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo
The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo
Pharmaceuticals
Business /  China Business

Fierce competition in China’s nascent immuno-therapy cancer drugs market could compromise safety, say analysts

As the market grows it will inevitably fragment into tiers of treatments with varying degrees of effectiveness and safety, according to a report by Nomura

Topic |   Pharmaceuticals
Eric Ng
Eric Ng

Updated: 6:30am, 13 Aug, 2018

Why you can trust SCMP
The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo
The Chinese market for anti-PD-1 medicine – a form of immuno-therapy treatment for cancer – could grow from virtually nothing this year to US$5.8 billion in the next four years. Photo: Alamy Stock Photo
READ FULL ARTICLE